
    
      Criteria for inclusion Signed written informed consent Male or female ≥18 years of age
      Cito-histological diagnosis of NSCLC, stage IV Performance Status = 0 or 1 Measurable disease
      on CT scan - RECIST criteria White blood count ≥ 3 x 109/L, Neutrophils ≥ 1.5 x 109/L,
      platelets ≥ 100 x 109/L, and hemoglobin ≥ 9 g/dL Bilirubin level either normal or ≤1.5 x ULN
      ASAT and ALAT ≤ 2.5 x ULN (or 5 x ULN in case of liver metastases) Alkaline phosphatase ≤ 2,5
      x ULN or ≤ 5 x ULN in case of bone metastases Creatinine clearance ≥ 50 ml/min Negative
      pregnancy test within one week before treatment start, if applicable Life expectancy of ≥ 3
      months Availability of tumor sample (or able and willing to provide tumor sample) for EGFR
      assessment Effective contraception for both male and female patients if the risk of
      conception exists Criteria for exclusion Documented or symptomatic brain metastases Previous
      chemotherapy for NSCLC including adjuvant chemotherapy Concurrent chronic systemic immune
      therapy, chemotherapy, or hormone therapy not indicated in the study protocol Any
      investigational agent(s) within 4 weeks prior to entry Major surgery within 4 weeks prior to
      study entry Prior chest irradiation within 12 weeks prior to study entry (palliative
      radiation of bone lesions is allowed) Superior vena cava syndrome contra-indicating
      hydratation Previous exposure to EGF, monoclonal antibodies, signal transduction inhibitors
      or EGFR targeting therapy Myocardial infraction within 6 months prior to study entry,
      uncontrolled congestive heart failure; or any current grade 3 or 4 cardio-vascular disorder
      despite treatment Known allergic / hypersensitivity reaction to any of the components of
      study treatments Known drug abuse/ alcohol abuse Legal incapacity or limited legal capacity
      Symptomatic peripheral neuropathy (NCI-CTC) ≥ 2 and/or ototoxicity grade ≥ 2 , except if due
      to trauma or mechanical impairment due to tumor mass Medical or psychological condition which
      in the opinion of the investigator would not permit the patient to complete the study or sign
      meaningful informed consent Pregnancy or breastfeeding Any previous or concurrent malignancy
      other than nonmelanoma skin cancer, or carcinoma in situ of the cervix. (Patients with a
      previous malignancy but without evidence of disease for > 5 years will be allowed to enter
      the trial)
    
  